TNNI3 and coronary artery disorder: To confirm the relevance of this proposed Hs-cTnI cutoff of 9.75 pg/mL, we compared clinical and biological results in the study population and found that patients with Hs-cTnI above 9.75 pg/mL were older (p = 0.01) and more likely to get a β-blocker prescription (p = 0.034), angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) therapy (respectively, p = 0.005 for ACEi or ARBs and p = 0.021 for ARBs alone), or a history of coronary heart disease (p = 0.016) (Supplementary Table 3).